Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. paprat

PAPRAT SIGNED

PAPRAT (Predictive Algorithm for Pre-Rheumatoid Arthritis Treatment). The new and most efficient multiple biomarkers-based system for an early selection of RA treatment intensity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PAPRAT project word cloud

Explore the words cloud of the PAPRAT project. It provides you a very rough idea of what is the project "PAPRAT" about.

poorly    ageing    remission    demographical    bn    1    yearly    algorithm    continued    citrullinated    calculate    ra    globally    unclassified    index    protein    efficient    needing    disability    licensing    45    pain    spent    optimize    biosimilars    economic    prognosis    accuracy    40    17    validate    acpa    good    complications    difficult    rf    suffering    delays    paprat    degenerative    outcome    lack    treatment    medium    prognostics    biomarker    deterioration    aggressive    markers    population    severity    proper    complete    prepare    software    burden    combines    biological    rheumatoid    total    launch    drivers    unnecessary    variables    multiple    genetics    blood    arthritis    genetic    therapy    personalized    reduce    classify    organs    antibodies    dmards    patients    trl6    critical    service    designed    82    combined    bone    4    joints    addressable    disease    spanish    finished    once    health    classifying    world    3m    medicine    clinical    start    market    genomic    platform    discerning    grow    administration    few    anti    deformity    epigenetic    predictive    accurate    leave   

Project "PAPRAT" data sheet

The following table provides information about the project.

Coordinator		 MAKING GENETICS S.L. 

Organization address
address: PLAZA CEIN 1, POLIGONO MOCHOLI, OFICINA R1.9, NOAIN
city: NOAIN
postcode: 31110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAKING GENETICS S.L. ES (NOAIN) coordinator 50˙000.00

Map

 Project objective

Rheumatoid arthritis (RA) affects 1% of world population (17.6 M) and it is a relevant economic burden (€45 Bn spent yearly in Europe). It is a degenerative disease that affects bone health, cause joints’ deformity, impact other organs and cause disability. An early and personalized treatment can greatly improve its outcome, achieve remission and reduce pain, thus an accurate prognosis is critical for its efficient management. However, this is difficult for the lack of good prognosis factors (currently rheumatoid factor-RF or anti-citrullinated protein antibodies-ACPA), which at present are very few, poorly accurate and leave 40% of patients unclassified (suffering health complications due to an unnecessary aggressive treatment or from deterioration due to delays in proper treatment). Making Genetics is a Spanish start-up focused in personalized medicine through genomic approaches. We have designed and developed a prognostics test for RA based on a blood test and the use of our new PAPRAT algorithm, with 82.4% accuracy. PAPRAT is a multiple biomarker-based system capable of classifying pre-rheumatoid arthritis patients, discerning which will need a more aggressive treatment. It combines unique genomic markers (genetic and epigenetic), as well as clinical and demographical variables, to calculate a predictive index and classify patients’ RA severity as HIGH (needing early administration of a combined therapy with biological DMARDs) or LOW and MEDIUM (non-biological DMARDs are enough). It is at a TRL6 and now we aim to optimize it, further validate it, develop a software platform and prepare its market launch. RA is expected to grow by drivers such as an ageing population or the continued uptake of biosimilars, and we have currently a total addressable market of 17.6 M patients globally and of around 3M in Europe. We will offer a complete prognosis service, including the blood testing, as well as the licensing of our software platform once it is finished.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAPRAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PAPRAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More